Elie Traer
Associate Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine · Oregon Health & Science University
Credentials: · · · ·
History
Research
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
New England Journal of Medicine · 2018 · 1,234 citations
Functional genomic landscape of acute myeloid leukaemia
Nature · 2018 · 1,111 citations
Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation
Genes & Development · 2003 · 512 citations
33 papers
- RS
17 papers
15 papers
- ES
14 papers
- JD
14 papers
14 papers · 10 as a resident
13 papers
13 papers
Grants
- 2026–2031
HuMarrow: A Primary Cell Model of AML and Normal Marrow to Accelerate Translational Research
National Cancer Institute · R01
Contact PI · $638.9K · Oregon Health & Science University
Clinical trials
- 2021–2026
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 1
OHSU Knight Cancer Institute
- 2018–2020
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Principal investigator · Terminated · Phase 2
OHSU Knight Cancer Institute
- 2019–2027
Site PI · Recruiting · Phase 1, Phase 2
Syndax Pharmaceuticals